Search Within

Abbas Nazir

Formats
  1. Journal Article (6)
  2. Meeting Abstract (3)
Groups
  1. Center for Hematologic Malignancies (9)
  2. Department of Medicine (9)
  3. Executive Committee, Center for Hematologic Malignancies (9)
  4. GSK Faculty (9)
  5. Hematologic Malignancies, Division of (9)
  6. Human Oncology and Pathogenesis Program (9)

More Groups

People
  1. Ross Levine (8)
  2. Alan Shih (5)
  3. Kaitlyn Shank (4)
  4. Andrew Dunbar (3)
  5. Elodie Pronier (3)
  6. Franck Rapaport (3)

More People

Years
  1. 2024 (1)
  2. 2022 (1)
  3. 2020 (1)
  4. 2018 (2)
  5. 2017 (3)
  6. 2016 (1)
Publications
  1. Blood (3)
  2. Cancer Discovery (2)
  3. Cancer Cell (1)
  4. Cancer Research (1)
  5. Current Protocols in Pharmacology (1)
  6. Nature (1)
Publishers
  1. American Association for Cancer Research (3)
  2. American Society of Hematology (3)
  3. Cell Press (1)
  4. John Wiley & Sons (1)
  5. Nature Publishing Group (1)

Results (9)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Jak2(V617F) reversible activation shows its essential requirement in myeloproliferative neoplasms
    Journal Article

    Dunbar, A. J.; Bowman, R. L.; Park, Y. C.; O'Connor, K.; Izzo, F.; Myers, R. M.; Karzai, A.; Zaroogian, Z.; Kim, W. J.; Fernandez-Maestre, I.; more...
    Cancer Discovery (2024)

    Fulltext@MSK | Save
  • JAK2(V617F) reversible activation shows an essential requirement for JAK2(V617F) in myeloproliferative neoplasms (MPNs)
    Meeting Abstract

    Dunbar, A.; Bowman, R. L.; Park, Y.; Izzo, F.; Myers, R. M.; Karzai, A.; Kim, W. J.; Maestre, I. F.; Waarts, M. R.; Nazir, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • The protein phosphatase 4 complex is a tumor suppressor in prostate cancer
    Meeting Abstract

    Watson, P. A.; Lawrence, K. E.; Nadkarni, T. V.; Ishmael, T. F.; Lee, E.; Agudelo Rivera, A. C.; Love, J. R.; Wongvipat, J.; Cai, L.; Nazir, A.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity
    Journal Article

    Kunimoto, H.; Meydan, C.; Nazir, A.; Whitfield, J.; Shank, K.; Rapaport, F.; Maher, R.; Pronier, E.; Meyer, S. C.; Garrett-Bakelman, F. E.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
    Journal Article

    Intlekofer, A. M.; Shih, A. H.; Wang, B.; Nazir, A.; Rustenburg, A. S.; Albanese, S. K.; Patel, M.; Famulare, C.; Correa, F. M.; Takemoto, N.; more...
    Nature (2018)

    Fulltext@MSK | Save
  • Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells
    Journal Article

    Kunimoto, H.; McKenney, A. S.; Meydan, C.; Shank, K.; Nazir, A.; Rapaport, F.; Durham, B.; Garrett-Bakelman, F. E.; Pronier, E.; Shih, A. H.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Overview of transgenic mouse models of myeloproliferative neoplasms (MPNs)
    Journal Article

    Dunbar, A.; Nazir, A.; Levine, R.
    Current Protocols in Pharmacology (2017)

    Fulltext@MSK | Save
  • Combination targeted therapy to disrupt aberrant oncogenic signaling and reverse epigenetic dysfunction in IDH2- and TET2-mutant acute myeloid leukemia
    Journal Article

    Shih, A. H.; Meydan, C.; Shank, K.; Garrett-Bakelman, F. E.; Ward, P. S.; Intlekofer, A. M.; Nazir, A.; Stein, E. M.; Knapp, K.; Glass, J.; more...
    Cancer Discovery (2017)

    Fulltext@MSK | Save
  • Cooperative epigenetic remodeling by TET2 loss and NRAS mutation drives myeloid transformation and MEK inhibitor sensitivity
    Meeting Abstract

    Kunimoto, H.; Meydan, C.; Nazir, A.; Shank, K.; Maher, R.; Rapaport, F.; Pronier, E.; Melnick, A.; Levine, R. L.; Shih, A. H.
    Blood (2016)

    Fulltext@MSK | Save